Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether low-dose cytarabine in
combination with arsenic trioxide is more effective than low-dose cytarabine alone in
achieving complete remission in elderly patients (≥60 years of age) with acute myeloid
leukemia.